Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

C-Fog is a collaborative new study led by Oxford University researcher, Dr Maxime Taquet, which will investigate the reasons why brain fog or cognition problems affect patients after COVID-19 infection. With a better understanding of the mechanisms involved it may be possible to understand how to treat brain fog and help many thousands of people worldwide.

Side profile of a sad man losing parts of head as symbol of decreased mind function

The study collaboration involves the Department of Psychiatry, the Nuffield Department of Clinical Neurosciences, and the Oxford Centre for Human Brain Activity at the University of Oxford, Imperial College London and the National Institute for Health (NIHR) Research Leicester Biomedical Research Centre (BRC).

This new study follows on from the NIHR Leicester BRC led PHOSP-COVID study, which investigated the long-term health impacts of COVID-19 on hospitalised patients, the C-MORE study, which aimed to understand the medium-term and long-term effects of COVID-19 on the organs, and the COVID-19 Clinical Neuroscience Study (COVID-CNS), which investigates people who had neurological or neuropsychiatric symptoms whilst acutely ill.

Participants for the C-Fog study will be recruited from the participants in the original PHOSP-COVID study. There will be two avenues of assessment, one using a new online tool - COGNITRON, which is a comprehensive cognitive assessment and was created by Professor Alan Hampshire, Imperial College London, and another where further imaging and scans of brain function will be carried out.

This study is funded by a grant from the Wolfson Foundation and supported by the MQ Mental health research charity.

Dr Maxime Taquet, study lead, said:

'This is a wonderful opportunity to learn more about "brain fog" and builds on the great work done by the PHOSP-COVID study investigators and participants. We are enormously grateful to the Wolfson Foundation and MQ Transforming Mental Health for funding C-Fog. I have met several patients with "brain fog" following COVID infection, and they have told me how distressing and debilitating this problem can be. One encounter that stuck with me was a gentleman who had been running his own business successfully for years and had to stop because he was finding simple tasks too confusing. I am hopeful that this study will deliver answers to important questions about these symptoms and what is happening in the brain after COVID infection, both to help these patients and, more generally, perhaps to help us understand how the brain responds to viral infection.'

The study aims to start recruitment in early Spring and researchers will simultaneously analyse existing data from two major studies, PHOSP-COVID and C-MORE, alongside electronic health record data, to develop ideas and possible explanations for what is happening in the brains of people affected by COVID-19 infection.


Paul Ramsbottom, Chief Executive, Wolfson Foundation, said:


'The long-term impact of COVID-19 infection is poorly understood. It is, however, sadly clear that the long-term health effects will be profound - and be felt in societies across the globe. Wolfson has a longstanding interest in the research and treatment of neurological conditions and we are very pleased to be supporting MQ and their research partners in this crucial work.'

To read more about MQ Mental health research.


Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Ethics at Westminster: A Workshop on Public Values and the Pandemic

At an event organised by the UK Pandemic Ethics Accelerator at the House of Commons on 18 May 2022, parliamentarians, policy makers and academics joined together to discuss how to bring ethical thinking and debate into public policy on pandemic recovery and preparedness, and how to involve the public.

New Study Shows Simvastatin Can Change the Way People Experience Certain Emotions

This new study examines the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation.

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.

Anxiety Disorders Among Children, Assessment and Working with Families

Anxiety disorders are the most common mental health disorders among children, yet there is limited guidance on the process of assessing child anxiety disorders and sharing diagnostic outcomes with families.

Landmark New Clinical Trial Shows Benefits of Automated Virtual Reality (VR) Treatment for Severe Psychological Problems

The gameChange automated VR program is designed to treat agoraphobia in patients with psychosis. In the largest ever clinical trial of virtual reality for mental health, gameChange especially helped people whose anxiety had previously left them virtually housebound.

UK-Japanese Collaboration Researches Mental Health Challenges Faced by Young People and their Families

Dr Simona Skripkauskaite, Departments of Psychiatry and Experimental Psychology, University of Oxford, is the UK lead for one of the ten collaborative research projects jointly awarded by the Economic and Social Research Council (ESRC), the Arts and Humanities Research Council (AHRC) and the Japan Society for the Promotion of Science (JSPS), to address the challenges presented by the global pandemic.